Deprescribing antihypertensive medication is not associated with the risk for hospitalization for myocardial infarction (MI) ...

Researchers have reported better long-term results of coronary artery bypass grafting (CABG) than of percutaneous coronary ...

Research on hormone therapy reveals critical insights into cardiovascular disease risks, guiding clinicians in selecting ...

Financially, Verve has a market cap of $475mn, cash balance of $540mn, and a cash runway of 7-8 quarters. Find out my ...

A new study supports previous data demonstrating the superiority of prasugrel over ticagrelor in reducing the composite outcome of mortality, myocardial infarction, or stroke in patients with acute ...

After more than a decade of research, experts have revealed a worrying reality for people taking certain hormone medications ...

Risk for all-cause mortality and MACEs are affected by calcified and low-attenuation plaque burdens in patients with chronic kidney disease.

BusinessWire India Mumbai Maharashtra [India] 3 SMT Sahajanand Medical Technologies a global leader in cardiovascular devices ...

The risk for recurrent cardiovascular events is high among patients with r-axSpA and a history of these events, though TNF inhibitor therapy may offer protective benefits.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Akebia Therapeutics®, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the ...

A new study has found that hormone replacement therapy, or HRT, used to alleviate the symptoms of the menopause, may be ...